A PHASE III/IV OPEN-LABEL STUDY OF THE IMMUNOGENICITY AND SAFETY OF A SINGLE DOSE OF A LIVE ATTENUATED INFLUENZA VACCINE (LAIV) (FLUENZTM) FOR EACH OF THREE SUCCESSIVE YEARS IN CHILDREN NAÏVE TO, OR IN PREVIOUS RECEIPT OF THE AS03B ADJUVANTED H1N1 (2009) INFLUENZA VACCINE (PANDEMRIX ™).: